Celanese Announces Commercial Launch of Glaukos’ iDose TR Travoprost Implant

Celanese announced the commercial launch Feb. 29 of Glaukos’ iDose TR intracameral travoprost implant for glaucoma.

Celanese, a global specialty materials and chemical company based in Dallas, Texas, produces VitalDose, the ethylene vinyl acetate copolymer that elutes the drug in Glaukos’ implant.

The iDose TR was approved by the US FDA in December 2023 and indicated for the reduction of intraocular pressure in patients with ocular hypertension or open-angle glaucoma. It is a 1.8 mm titanium implant designed to allow continuous elution of preservative-free travoprost directly into the anterior chamber. It is implanted through the trabecular meshwork and back wall of Schlemm’s canal, anchored directly into scleral tissue.

The implant was designed to be removed and replaced, but approval was granted for only a single administration.

Glaukos, of Aliso Viejo, California, said at the time of approval that it would target patients who aren’t complying with their glaucoma drop therapy; those who are intolerant to topical drops; those who have underlying ocular surface disease; and those who have physical limitations that prevent them from correctly dosing eye drops.

Glaukos said the rollout would involve targeted surgeon training; an application for a permanent J-code; and the establishment of a Category III CPT code for procedure and facility fees. The company set the wholesale acquisition cost for iDose TR of $13,950 per implant.